Abstract
We studied the prevalence of genetic thrombophilic mutations in patients on chronic oral anticoagulant treatment (OAT) who had bleeding complications. In a case-control study we found ten (12.8%) carriers of factor V Leiden and two (2.5%) carriers of the PT20210A mutation among 78 patients with a history of moderate-severe bleeding while on OAT, and seven (4.4%) and four (2.5%), respectively, among 156 matched patients with no bleeding while on OAT (odds ratio 3.1+/-1.6, p=0.026). In patients on chronic OAT, FV Leiden is a risk factor for moderate-severe bleeding.
MeSH terms
-
3' Untranslated Regions
-
Acenocoumarol / administration & dosage
-
Acenocoumarol / adverse effects
-
Administration, Oral
-
Aged
-
Aged, 80 and over
-
Anticoagulants / administration & dosage
-
Anticoagulants / adverse effects*
-
Case-Control Studies
-
Factor V / analysis
-
Factor V / genetics
-
Female
-
Follow-Up Studies
-
Gene Frequency
-
Hemorrhage / chemically induced*
-
Hemorrhage / genetics*
-
Hospitalization / statistics & numerical data
-
Humans
-
International Normalized Ratio
-
Male
-
Middle Aged
-
Prevalence
-
Prothrombin / genetics
-
Sample Size
-
Thrombophilia / epidemiology
-
Thrombophilia / genetics*
-
Warfarin / administration & dosage
-
Warfarin / adverse effects
Substances
-
3' Untranslated Regions
-
Anticoagulants
-
factor V Leiden
-
Warfarin
-
Factor V
-
Prothrombin
-
Acenocoumarol